Publication: Bone marrow-derived CD13+ cells sustain tumor progression: A potential non-malignant target for anticancer therapy
Loading...
Open/View Files
Date
2014
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Landes Bioscience
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Dondossola, Eleonora, Angelo Corti, Richard L Sidman, Wadih Arap, and Renata Pasqualini. 2014. “Bone marrow-derived CD13+ cells sustain tumor progression: A potential non-malignant target for anticancer therapy.” Oncoimmunology 3 (1): e27716. doi:10.4161/onci.27716. http://dx.doi.org/10.4161/onci.27716.
Abstract
Non-malignant cells found within neoplastic lesions express alanyl (membrane) aminopeptidase (ANPEP, best known as CD13), and CD13-null mice exhibit limited tumor growth and angiogenesis. We have recently demonstrated that a subset of bone marrow-derived CD11b+CD13+ myeloid cells accumulate within neoplastic lesions in several murine models of transplantable cancer to promote angiogenesis. If these findings were confirmed in clinical settings, CD11b+CD13+ myeloid cells could become a non-malignant target for the development of novel anticancer regimens.
Description
Other Available Sources
Research Data
Keywords
angiogenesis, tumor, CD13, mouse models, bone marrow-derived cells
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service